Comparative Pharmacology
Head-to-head clinical analysis: METHYLTESTOSTERONE versus NATESTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYLTESTOSTERONE versus NATESTO.
METHYLTESTOSTERONE vs NATESTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyltestosterone is a synthetic androgen that binds to and activates androgen receptors (AR) in target tissues, promoting the development and maintenance of male secondary sexual characteristics and anabolic effects. It also suppresses gonadotropin-releasing hormone (GnRH) secretion via negative feedback, reducing endogenous testosterone production.
Testosterone replacement therapy; testosterone binds to androgen receptors, activating gene transcription for male sexual development and maintenance of secondary sexual characteristics.
10-50 mg orally once daily or divided twice daily, or 10-25 mg buccally twice daily.
One 10 mg buccal tablet applied twice daily to the gum region above the incisor tooth, approximately 12 hours apart; morning and evening.
None Documented
None Documented
Clinical Note
moderateMethyltestosterone + Digoxin
"Methyltestosterone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethyltestosterone + Digitoxin
"Methyltestosterone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethyltestosterone + Deslanoside
"Methyltestosterone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMethyltestosterone + Acetyldigitoxin
2-4 hours (terminal); requires multiple daily dosing or transdermal route due to short half-life.
The terminal elimination half-life of testosterone after intramuscular injection of testosterone enanthate is approximately 8 days (range 4–12 days), reflecting slow absorption from the oily depot. This prolonged half-life supports a dosing interval of every 2–4 weeks.
Renal (primarily as glucuronide and sulfate conjugates, ~90%); fecal (~10%). Unchanged drug is minimal.
Following intramuscular administration of testosterone enanthate, approximately 90% of the dose is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites (e.g., androsterone, etiocholanolone). About 6% is excreted in feces via bile. Unchanged testosterone in urine is negligible (<1%).
Category D/X
Category C
Androgen
Androgen
"Methyltestosterone may decrease the cardiotoxic activities of Acetyldigitoxin."